Bristol-Myers Squibb Co. reported strong third-quarter sales of $920m for its PD-1 inhibitor Opdivo, and also a rebound for its CTLA-4 inhibitor Yervoy, but the company now has to brace for its market share to be eroded by new competition.
Sales of $920m for Opdivo (nivolumab), up 202% from the same period in 2015, were slightly lower than the Street...





